Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 27;13(7):1051.
doi: 10.3390/polym13071051.

Potential Role of Nanoparticles in Treating the Accumulation of Amyloid-Beta Peptide in Alzheimer's Patients

Mohamed Abbas  1   2
Affiliations
Review

Potential Role of Nanoparticles in Treating the Accumulation of Amyloid-Beta Peptide in Alzheimer's Patients

Mohamed Abbas. Polymers (Basel). .

Abstract

The disorder of Alzheimer's is marked by progressive pathophysiological neurodegeneration. The amino acid peptides in the amyloid plaques found in the brains of people with Alzheimer's disease (AD) are known as amyloid-beta (Aβ). Current treatments are not curative, and the effects associated with AD are reduced. Improving treatment results involved the targeting of drugs at optimum therapeutic concentration. Nanotechnology is seen as an unconventional, modern technology that plays a key role in the treatment of Alzheimer's disease. Using nanoparticles, molecular detection, effective drug targeting, and their combination offer high sensitivity. The aim of this review is to shed light on the function and successful role of nanoparticles to resolve Aβ aggregation and thus to help cure Alzheimer's disease. The analysis divides these nanoparticles into three categories: polymer, lipid, and gold nanoparticles. A thorough comparison was then made between the nanoparticles, which are used according to their role, properties, and size in the procedure. The nanoparticles can prevent the accumulation of Aβ during the efficient delivery of the drug to the cells to treat Alzheimer's disease. Furthermore, this comparison demonstrated the ability of these nanoparticles to deal efficiently with Alzheimer's disease. The role of these nanoparticles varied from delivering the drug to brain cells to dealing with the disease-causing peptide.

Keywords: Alzheimer’s; amyloid beta-peptide; drug delivery; lipids; nanodrugs; nanoparticles.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
Effects of different types of nanoparticles on the treatment of Alzheimer’s disease (AD).
Figure 2
Figure 2
The role of polymeric nanoparticles on the treatment of AD.
Figure 3
Figure 3
Different types of lipid nanoparticles used in the treatment of AD.
Figure 4
Figure 4
The structure of gold nanoparticles used in the treatment of AD.
Figure 5
Figure 5
Different sizes of polymeric nanoparticles used in AD treatment.
Figure 6
Figure 6
Different sizes of lipid nanoparticles used in AD treatment.
Figure 7
Figure 7
Different sizes of gold nanoparticles used in AD treatment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Fonseca-Santos B., Gremião M.P., Chorilli M. Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease. Int. J. Nanomed. 2015;10:4981–5003. doi: 10.2147/IJN.S87148. - DOI - PMC - PubMed
    1. Lauretti E., Dincer O., Praticò D. Glycogen synthase kinase-3 signaling in Alzheimer’s disease. Biochim. Biophys. Acta Mol. Cell Res. 2020;1867:118664. doi: 10.1016/j.bbamcr.2020.118664. - DOI - PMC - PubMed
    1. Liu R., Yang J., Liu L., Lu Z., Shi Z., Ji W., Shen J., Zhang X. An “Amyloid-β Cleaner” for the Treatment of Alzheimer’s Disease by Normalizing Microglial Dysfunction. Adv. Sci. 2020;7 doi: 10.1002/advs.201901555. - DOI - PMC - PubMed
    1. Gupta J., Fatima M., Islam Z., Khan R., Uversky V., Salahuddin P. Nanoparticle formulations in the diagnosis and therapy of Alzheimer’s disease. Int. J. Biol. Macromol. 2019;130:515–526. doi: 10.1016/j.ijbiomac.2019.02.156. - DOI - PubMed
    1. Cai J., Dao P., Chen H., Yan L., Li Y., Zhang W., Li L., Du Z., Dong C., Meunier B. Ultrasmall superparamagnetic iron oxide nanoparticles bound NIR dyes: Novel theranostic agents for Alzheimer’s disease. Dye. Pigment. 2020;173:107968. doi: 10.1016/j.dyepig.2019.107968. - DOI

LinkOut - more resources